Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression

Cancer Research

Volumn 63, Issue 18, 2003, Pages 5844-5849

  Andarawewa, Kumari L ^a   Boulay, Anne ^a   Masson, Régis ^a   Mathelin, Carole ^a   Stoll, Isabelle ^a   Tomasetto, Catherine ^a   Chenard, Marie Pierre ^b   Gintz, Martine ^b   Bellocq, Jean Pierre ^b   Rio, Marie Christine ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

STROMELYSIN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL SURVIVAL; CONNECTIVE TISSUE; CONTROLLED STUDY; FIBROBLAST; METASTASIS; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR GROWTH;

ANIMALS; CELL TRANSFORMATION, VIRAL; FEMALE; GENES, RAS; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MATRIX METALLOPROTEINASE 11; METALLOENDOPEPTIDASES; MICE; MICE, TRANSGENIC;

EID: 0141731300     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Raff, M. C. Social controls on cell survival and cell death. Nature (Lond.), 356: 397-400, 1992.
2. Meredith, J. E., Jr., Fazeli, B., and Schwartz, M. A. The extracellular matrix as a cell survival factor. Mol. Biol. Cell, 4: 953-961, 1993.
3. Frisch, S. M., and Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol., 124: 619-626, 1994.
4. Radisky, D., Hagios, C., and Bissell, M. J. Tumors are unique organs defined by abnormal signaling and context. Semin. Cancer Biol., 11: 87-95, 2001.
5. Basset, P., Okada, A., Chenard, M. P., Kannan, R., Stoll, I., Anglard, P., Bellocq, J. P., and Rio, M. C. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol., 15: 535-541, 1997.
6. Nagase, H., and Woessner, J. F., Jr. Matrix metalloproteinases. J. Biol. Chem., 274: 21491-21494, 1999.
7. McCawley, L. J., and Matrisian, L. M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol., 13: 534-540, 2001.
8. Overall, C. M., and Lopez-Otin, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer, 2: 657-672, 2002.
9. Rio, M. Stromelysin-3, a particular member of the matrix metalloproteinase family, Vol. 5, pp. 81-107. Kluwer Academic, 2002.
10. Basset, P., Bellocq, J. P., Lefebvre, O., Noel, A., Chenard, M. P., Wolf, C., Anglard, P., and Rio, M. C. Stromelysin-3: a paradigm for stroma-derived factors implicated in carcinoma progression. Crit. Rev. Oncol. Hematol., 26: 43-53, 1997.
11. Mari, B. P., Anderson, I. C., Mari, S. E., Ning, Y., Lutz, Y., Kobzik, L., and Shipp, M. A. Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism. J. Biol. Chem., 273: 618-626, 1998.
12. Wang, C. S., and Tetu, B. Stromelysin-3 expression by mammary tumor-associated fibroblasts under in vitro breast cancer cell induction. Int. J. Cancer, 99: 792-799, 2002.
13. Rio, M. C., Lefebvre, O., Santavicca, M., Noel, A., Chenard, M. P., Anglard, P., Byrne, J. A., Okada, A., Regnier, C. H., Masson, R., Bellocq, J. P., and Basset, P. Stromelysin-3 in the biology of the normal and neoplastic mammary gland. J. Mammary Gland. Biol. Neoplasia, 1: 231-240, 1996.
14. Masson, R., Lefebvre, O., Noel, A., Fahime, M. E., Chenard, M. P., Wendling, C., Kebers, F., LeMeur, M., Dierich, A., Foidart, J. M. Basset, P., and Rio, M. C. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol., 140: 1535-1541, 1998.
15. Boulay, A., Masson, R., Chenard, M. P., El Fahime, M., Cassard, L., Bellocq, J. P., Sautes-Fridman, C., Basset, P., and Rio, M. C. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res., 61: 2189-2193, 2001.
16. Wu, E., Mari, B. P., Wang, F., Anderson, I. C., Sunday, M. E., and Shipp, M. A. Stromelysin-3 suppresses tumor cell apoptosis in a murine model. J. Cell Biochem., 82: 549-555, 2001.
17. Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., and Leder, P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell, 49: 465-475, 1987.
18. Forrester, K., Almoguera, C., Han, K., Grizzle, W. E., and Perucho, M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature (Lond.), 327: 298-303, 1987.
19. Bos, J. L., Fearon, E. R., Hamilton, S. R., Verlaan-de Vries, M., van Boom, J. H., van der Eb, A. J., and Vogelstein, B. Prevalence of ras gene mutations in human colorectal cancers. Nature (Lond.), 327: 293-297, 1987.
20. Balmain, A., Ramsden, M., Bowden, G. T., and Smith, J. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature (Lond.), 307: 658-660, 1984.
21. Guerrero, I., and Pellicer, A. Mutational activation of oncogenes in animal model systems of carcinogenesis. Mutat. Res., 185: 293-308, 1987.
22. Comoglio, P. M., and Trusolino, L. Invasive growth: from development to metastasis. J. Clin. Investig., 109: 857-862, 2002.
23. Hundley, J. E., Koester, S. K., Troyer, D. A., Hilsenbeck, S. G., Subler, M. A., and Windle, J. J. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53, Mol. Cell. Biol., 17: 723-731, 1997.
24. Kaplan, E. L. Non parametric estimation for incomplete information. J. Am. Stat. Assoc., 53: 457-481, 1958.
25. Squartini, F., Bistocchi, M., Sarnelli, R., and Basolo, F. Early pathologic changes in experimental and human breast cancer: facts and comments. Ann. N. Y. Acad. Sci., 464: 231-261, 1986.
26. McClatchey, A. I. Modeling metastasis in the mouse. Oncogene, 18: 5334-5339, 1999.
27. Chambers, A. F., Groom, A. C., and MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer. 2: 563-572, 2002.
28. Cardiff, R. D., Bern, H. A., Faulkin, L. J., Daniel, C. W., Smith, G. H., Young, L. J., Medina, D., Gardner, M. B., Wellings, S. R., Shyamala, G., Guzman, R. C., Rajkumar, L., Yang, J., Thordarson, G., Nandi, S., MacLeod, C. L., Oshima, R. G., Man, A. K., Sawai, E. T., Gregg, J. P., Cheung, A. T., and Lau, D. H. Contributions of mouse biology to breast cancer research. Comp. Med., 52: 12-31, 2002.
29. Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks. M. W., and Weinberg, R. A. Creation of human tumour cells with defined genetic elements. Nature (Lond.), 400: 464-468, 1999.
30. MacDonald, I. C., Groom, A. C., and Chambers, A. F. Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays, 24: 885-893, 2002.
31. Bernards, R., and Weinberg, R. A. A progression puzzle. Nature (Lond.), 418: 823, 2002.
32. Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L., and Matrisian, L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA, 94: 1402-1407, 1997.
33. Zucker, S., Cao, J., and Chen, W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene, 19: 6642-6650, 2000.
34. Coussens, L. M., Fingleton, B., and Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash. DC). 295: 2387-2392, 2002.
35. Kruger, A., Soeltl, R., Sopov, I., Kopitz, C., Arlt, M., Magdolen, V., Harbeck, N., Gansbacher, B., and Schmitt, M. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res., 61: 1272-1275, 2001.
36. Itoh, T., Tanioka, M., Yoshida, H., Yoshioka, T., Nishimoto, H., and Itohara, S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res., 58: 1048-1051, 1998.
37. Coussens, L. M., Tinkle, C. L., Hanahan, D., and Werb. Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103: 481-490, 2000.
38. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86: 353-364, 1996.
39. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., and Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (Wash. DC), 284: 808-812, 1999.
40. Dong, Z., Kumar, R., Yang, X., and Fidler, I. J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell, 88: 801-810, 1997.
41. Lijnen, H. R., Ugwu, F., Bini, A., and Collen, D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry, 37: 4699-4702, 1998.
42. Pozzi, A., LeVine, W. F., and Gardner, H. A. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene, 21: 272-281, 2002.
43. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., Barrera, J. L., Mohar, A., Verastegui, E., and Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature (Lond.), 410: 50-56, 2001.
44. Noel, A., Boulay, A., Kebers, F., Kannan, R., Hajitou, A., Calberg-Bacq, C. M., Basset, P., Rio, M. C., and Foidart, J. M. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene, 19: 1605-1612, 2000.
45. Mueller, M. M., and Fusenig, N. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation, 70: 486-497, 2002.
46. Yu. J. L., Coomber, B., and Kerbel, R. S. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation, 70: 599-609, 2002.